Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.
Bartsch R, De Vries C, Pluschnig U, Dubsky P, Bago-Horvath Z, Gampenrieder SP, Rudas M, Mader RM, Rottenfusser A, Wiltschke C, Gnant M, Zielinski CC, Steger GG.
Bartsch R, et al.
BMC Cancer. 2009 Oct 17;9:367. doi: 10.1186/1471-2407-9-367.
BMC Cancer. 2009.
PMID: 19835621
Free PMC article.